Sandra McCrary, PA
Physician Assistant · Kingsport, TNNPI 1699700922
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 61.7% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $7,601, 9.3 times the $814 reported in 2021. Among physician assistant clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $48.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- AstraZeneca$1K
- Novartis$1K
- Abbott$627
- Boehringer Ingelheim$476
- Merck$446
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$9,32654%
- Travel & lodging$5033%
- Food & beverage$7,45343%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $10,681 |
| AstraZeneca | 50 | $1,464 |
| Novartis | 114 | $1,412 |
| Abbott | 8 | $627 |
| Boehringer Ingelheim | 16 | $476 |
| Merck | 25 | $446 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $358 |
| Scpharmaceuticals Inc. | 8 | $237 |
| Lexicon Pharmaceuticals, Inc. | 7 | $224 |
| Cvrx, Inc. | 2 | $223 |
| Pfizer | 7 | $190 |
| Daiichi Sankyo Inc. | 6 | $150 |
| Bayer | 8 | $141 |
| E.r. Squibb & Sons, L.L.C. | 8 | $130 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 7 | $107 |
| Johnson & Johnson | 7 | $91 |
| Boston Scientific | 4 | $87 |
| Daxor Corporation | 3 | $55 |
| Stryker | 1 | $44 |
| Novo Nordisk | 1 | $32 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$9,814
- FARXIGA$371
- LOKELMA$250
- JARDIANCE$224
- Barostim Neo System$192
- CARDIOMEMS$150
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
- MitraClip$149
- UPTRAVI$125
- OPSUMIT$125
- FUROSCIX$125
- Inpefa$120
How this compares
$17,314 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 934 | $844,863 |
| Repatha SureclickEvolocumab | 486 | $397,645 |
| JardianceEmpagliflozin | 438 | $362,705 |
| FarxigaDapagliflozin Propanediol | 414 | $326,681 |
| EliquisApixaban | 168 | $149,622 |
| FuroscixFurosemide | 15 | $94,930 |
| Praluent PenAlirocumab | 86 | $59,460 |
| XareltoRivaroxaban | 34 | $44,963 |
| VascepaIcosapent Ethyl | 40 | $21,837 |
| Repatha SyringeEvolocumab | 14 | $12,303 |
| BrilintaTicagrelor | 14 | $12,262 |
| Metoprolol Succinate | 613 | $9,011 |
| VerquvoVericiguat | 11 | $7,692 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,229 |
| Valsartan | 92 | $4,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,412 | $844,863934 claims |
| Boehringer IngelheimJardiance | $476 | $362,705438 claims |
| AstraZenecaFarxiga, Brilinta | $1,464 | $338,943428 claims |
| PfizerEliquis | $190 | $149,622168 claims |
| Scpharmaceuticals Inc.Furoscix | $237 | $94,93015 claims |
| Johnson & JohnsonXarelto | $91 | $44,96334 claims |
| MerckVerquvo | $446 | $7,69211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Kingsport
- Philip WeatherfordKingsport$16K
- William JohnsonKingsport$13K
- Harold LittleKingsport$13K
- Rachel RiceKingsport$11K
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$187K
- Katherine RunyanKnoxville$156K
- Robert LaughertyAlcoa$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.